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Altered Metabolism of the Amyloid 
Precursor Protein Is Associated with
Mitochondrial Dysfunction in Down’s Syndrome
increased gene dosage, leading to increased Agenera-
tion (Prasher et al., 1998; Selkoe, 2001). This is consis-
tent with increased plasma levels of A42 in DS patients
(Schupf et al., 2001) and the detection of soluble A42
in the brains of DS, but not control subjects, as early
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Farmington, Connecticut 06030 DS brains during childhood (Lemere et al., 1996).
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Harvard Medical School and ronal degeneration and may be involved in a number of
neurodegenerative disorders (Beal, 1995; Murphy et al.,Division of Neuroscience
The Children’s Hospital 1999). In DS, there are reduced levels of NADH3 (mito-
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300 Longwood Avenue plex V (ATP synthase)  chain protein in cortex (Krapfen-
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3 Department of Neuroscience mitochondrial DNA repair is impaired after oxidative
damage in DS fibroblasts (Druzhyna et al., 1998). Fur-Osaka City University Medical School
1-4-3 Asahimachi thermore, DS cortical neurons in culture exhibit intracel-
lular accumulation of reactive oxygen species (ROS) andAbenoku 545-8585
Japan increased lipid peroxidation leading to neuronal apopto-
sis (Busciglio and Yankner, 1995). Interestingly, pertur-
bations of mitochondrial homeostasis constitute an
early and critical feature of apoptotic processes thatSummary
precedes free radical formation and neuronal death
(Zamzami et al., 1995), raising the possibility that alter-Most Down’s syndrome (DS) patients develop Alzhei-
mer’s disease (AD) neuropathology. Astrocyte and ations in mitochondrial energy metabolism may be di-
rectly associated with oxidative stress (Odetti et al.,neuronal cultures derived from fetal DS brain show
alterations in the processing of amyloid  precursor 1998; Nunomura et al., 2000) and apoptosis in DS. En-
ergy depletion and oxidative stress can also induce amy-protein (APP), including increased levels of APP and
C99, reduced levels of secreted APP (APPs) and C83, loidogenic changes in APP processing (Gabuzda et
al., 1994; Frederikse et al., 1996; Gasparini et al., 1997;and intracellular accumulation of insoluble A42. This
pattern of APP processing is recapitulated in normal Misonou et al., 2000), suggesting a potential link be-
tween mitochondrial dysfunction, oxidative stress, andastrocytes by inhibition of mitochondrial metabolism,
consistent with impaired mitochondrial function in DS A production. In this regard, dysfunction of mitochon-
drial electron transport proteins and a close relationshipastrocytes. Intracellular A42 and reduced APPs are
also detected in DS and AD brains. The survival of between mitochondrial abnormalities and oxidative
damage have been described in AD brains (Blass andDS neurons is markedly increased by recombinant or
astrocyte-produced APPs, suggesting that APPs Gibson, 1991; Hirai et al., 2001; Valla et al., 2001).
To characterize the molecular events involved in DSmay be a neuronal survival factor. Thus, mitochondrial
dysfunction in DS may lead to intracellular deposition neuropathology and the development of AD in DS, we
analyzed APP processing, A generation, and mito-of A42, reduced levels of APPs, and a chronic state
of increased neuronal vulnerability. chondrial activity in normal and DS cortical astrocytes
in culture and in the DS brain. Our findings suggest that
mitochondrial dysfunction may play a significant role inIntroduction
the development of AD neuropathology in DS patients by
promoting aberrant APP processing and intracellularDown’s syndrome (DS) or trisomy 21 is the most com-
mon genetic cause of mental retardation. The neuropa- accumulation of A.
thology of DS is complex and includes decreased brain
weight, decreased neuronal number, abnormal neuronal Results
differentiation, and structural changes in dendritic
spines (reviewed by Coyle et al., 1986). A distinct feature Altered APP Processing and Accumulation
of DS is the onset of Alzheimer’s disease (AD) by middle of Intracellular A in DS Astrocytes
age (Coyle et al., 1986; Mann, 1988). Although the Primary cultures of DS fetal cortex were used to examine
gene(s) responsible for the neuropathology associated the processing of APP and its potential role in the
with DS have not yet been fully characterized, the devel- neuropathology of DS. We have previously shown that
opment of AD in DS may be related to the overexpres- cultured DS cortical neurons undergo apoptosis due to
sion of the amyloid  precursor protein (APP) due to intracellular accumulation of reactive oxygen species
(Busciglio and Yankner, 1995). Thus, to avoid secondary
effects of degeneration on APP metabolism (LeBlanc,4 Correspondence: busciglio@nso1.uchc.edu
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relative to normal astrocytes (Figure 1A). Using antibody
C8 to the APP C terminus, we examined the - and
-secretase generated C-terminal fragments (CTFs) of
APP. Surprisingly, the level of C83, the nonamyloido-
genic CTF generated by -secretase cleavage, was
markedly reduced by 48.5%  16.2% in DS astrocytes
compared to normal astrocytes (Figure 1B). In contrast,
the level of C99, the CTF generated by -secretase
cleavage, was markedly increased by 168%  25.5%
in DS cultures (Figure 1B). This result was confirmed by
using the monoclonal antibody 6E10 generated against
amino acids 1–17 of A (Figure 1B, lower panel). These
results suggest that there is a selective increase in
-secretase cleavage and a decrease in -secretase
cleavage of APP in DS astrocytes.
We also examined the levels of the secreted ectodomain
of APP (APPs) and A (As) in the conditioned medium
of astrocyte cultures. Despite the increase in holo-APP
observed in DS astrocytes, As and APPs were re-
duced to 62.7%  14.9% and 60.7%  12.1%, respec-
tively, in the conditioned media of DS cultures compared
to normal cultures (Figures 1A and 1C). The reduction
in APPs was observed after immunoprecipitation with
antibody Alz 90 against the APP N-terminal domain,
as well as antibody B9 against the N-terminal domain
Figure 1. Altered Processing of APP in DS Astrocytes of A, which does not cross-react with APLPs. No signifi-
(A) Increased holo-APP and reduced APPs in DS astrocytes. Holo- cant changes were observed in the levels of secreted
APP and APPs were immunoprecipitated from the cell lysate
1-antichymotrypsin and syndecan (data not shown), sug-(cellular) and conditioned medium (secreted), respectively, of normal
gesting that the reduction observed in APPs and As(NL) and Down’s syndrome (DS) astrocyte cultures. The samples
was not due to a general defect in protein secretion inwere separated using a 7% linear acrylamide gel to optimize separa-
tion of APP isoforms. Similar patterns of immature (imm) and ma- DS astrocytes. To determine whether A accumulated
ture (mat) APP isoforms were observed in normal and DS cultures. intracellularly in DS cells, A levels were examined in cell
Similar tubulin (Tub) levels were observed in normal and DS cell lysates. A significant amount of intracellular A (Ai) was
lysates. detected in DS astrocytes after 30 days in culture, while
(B) Reduced C83 and increased C99 levels in DS astrocytes. Cell
barely detectable levels of A were found in normallysates were immunoprecipitated with antibodies C8 against the
astrocyte lysates (Figure 1C). Preabsorption of the pri-C terminus of APP and 6E10 against residues 1–17 of A. Similar
mary antibody with synthetic A completely abolishedtubulin (Tub) levels were observed in normal and DS cell lysates.
(C) A secretion is reduced and cell-associated A (Ai) is increased the immunoprecipitation of Ai (Figure 1D). Ai was also
in DS astrocytes. A was immunoprecipitated with antibody B9. detected in DS cultures treated with trypsin before har-
(D) Cell-associated A is intracellular and is not derived from extra- vesting, suggesting that As bound to the cell surface
cellular A. Incubation of DS astrocytes with trypsin before cell lysis is not the source of Ai detected in DS cell lysates (Figuredid not reduce cell-associated A (tryps). Ai was not detected after
1D). Furthermore, when unlabeled DS astrocytes were in-incubation of unlabeled DS astrocytes with conditioned medium of
cubated with the conditioned medium of [35S]methionine-[35S]methionine-labeled DS astrocytes (cm). Preabsorption of the
labeled DS astrocytes and then lysed and immuno-A antibody with synthetic A peptide abolished immunoprecipita-
tion of intracellular A (Ai, preab). precipitated, Ai was not detected, suggesting that
(E) Detergent-insoluble Ai accumulates in DS astrocytes, but not internalization of As is not the source of Ai (Figure
normal (NL) astrocytes. Awas immunoprecipitated from the deter- 1D, cm). Thus, DS astrocytes exhibit reduced secretion
gent-resistant fraction of DS cell lysates with antibody B9, but not
of APP and A and accumulate intracellular A.after preabsorption of antibody B9 with A peptide (preab).
To determine whether the accumulation of Ai in DS(F) DS cortical neuronal cultures analyzed at 5 days in culture exhibit
astrocytes could lead to A deposition, we examinedincreased cellular APP levels (APP), intracellular accumulation of
the solubility state of Ai. DS astrocytes were lysed inA (Ai), and decreased levels of secreted APP (APPs) and A
(As). Samples were separated in a 4%–20% gradient gel. RIPA buffer, and the detergent-insoluble fraction was
separated by centrifugation. A was detected in the
detergent-insoluble pellet after solubilization by boiling
1995), we examined APP processing in primary cul- in 4% SDS (Figure 1E). Preabsorption of the primary
tures of DS astrocytes. Similar to normal astrocytes, DS antibody with synthetic A peptide completely abol-
astrocytes are completely viable in culture and secrete ished the immunoprecipitation of RIPA-insoluble Ai
significant amounts of APP and A (Busciglio et al., (Figure 1E). Tubulin, actin, and flotillin were found in
1993b; LeBlanc et al., 1997). Metabolic labeling and im- the RIPA-soluble fraction and were not detected in the
munoprecipitation experiments performed after 1 month RIPA-insoluble fraction (data not shown), suggesting
in culture showed that DS and normal astrocytes pro- that RIPA-insoluble Ai is not bound to cytoskeletal
duced similar immature and mature APP isoforms (Fig- structures or associated with membrane rafts. These
ure 1A). The level of cellular APP in DS astrocytes results suggest that A is retained intracellularly in DS
astrocytes and accumulates as insoluble aggregates.was increased significantly by 114.7%  33.6% (SEM)
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Similar changes in APP metabolism were observed
in DS cortical neurons analyzed at day 5 in culture before
the onset of neuronal degeneration in DS cultures (Bus-
ciglio and Yankner, 1995). DS neurons also exhibited
increased levels of holo-APP, intracellular accumula-
tion of A (Ai), and reduced secretion of APPs and
As (Figure 1F) indicating that altered processing of
APP and intracellular accumulation of A occur in both
DS cortical astrocytes and neurons.
To assess the intracellular localization of A, immuno-
fluorescence microscopy was performed in DS astro-
cytes using monoclonal antibodies generated against
the C terminus of A42 and A40 (Lippa et al., 1999).
These antibodies specifically recognized A42 and
A40, respectively, but not full-length APP (Figure 2A).
Antibody specificity was also confirmed by immunocy-
tochemical staining of synthetic A1-42 and A1-40 fi-
brils (data not shown). To resolve intracellular A42-
specific staining, a tyramide signal amplification system
was used. Minimal background staining was detected
in the cytoplasm of normal astrocytes (Figure 2B). In
contrast, DS astrocytes showed significant A42-posi-
tive labeling in a vesicular distribution, often forming
larger clusters in different regions of the cytoplasm (Fig-
ures 2C and 2D, arrows). A42 immunofluorescence was
completely abolished by preincubation of the primary
antibody with synthetic A1-42 peptide (data not shown).
A42 was also detected in DS astrocytes extracted with
Triton X-100 prior to fixation (Figure 2D), further sug-
gesting the presence of insoluble, detergent-resistant,
intracellular A42 aggregates. A40 immunoreactivity
was not detected in DS astrocytes. An electrophoretic
gel system that separates A40 from A42 (Wiltfang et
al., 1997) confirmed the presence of intracellular A42
in DS cortical cultures (data not shown). Immunocy-
tochemical analysis of Cu/Zn superoxide dismutase,
another protein overexpressed in DS, and tubulin, an
abundant cytoplasmic protein, showed no significant
difference in intracellular localization between control
and DS cultures (data not shown), suggesting a specific
mechanism in the accumulation and aggregation of Ai.
Double-labeling showed that Ai partially colocalized
with APP, which is associated with the subcellular
compartments of the secretory pathway (Figures 2E–
2G). Ai staining was particularly intense in perinuclear
regions where it partially colocalized with the Golgi-
Figure 2. Intracellular Accumulation of Aggregated A42 in DS
resident protein syntaxin 6 (Figures 2H–2J) and the early Astrocytes
endosome antigen 1 protein (EEA1) (Figures 2K–2M).
(A) Specificity of A antibodies. Western blot analysis of synthetic
Thus, intracellular A accumulates in subcellular com- A1-40, A1-42, and recombinant APP with monoclonal antibodies
partments associated with APP trafficking and pro- -A40, -A42, and polyclonal -A. Note that -A42 specifically
recognizes A1-42, but not A1-40 or APP.cessing.
(B–D) Intracellular A42 in DS astrocytes. Immunofluorescence of
normal (NL) and DS astrocyte cultures using -A42. Note the ap-Energy Depletion Induces DS-like Alterations
pearance of A42 labeling in a vesicular-like distribution in DS ([C
in APP Processing in Normal Astrocytes and D], arrows), but not normal astrocytes. Detergent-insoluble ag-
The alterations in APP metabolism observed in DS gregates of A42 appear in DS astrocytes extracted with Triton
X-100 before fixation (D).astrocytes were very similar to the changes in APP
(E–G) Double-labeling shows partial colocalization of A42 (A) withprocessing produced by energy depletion in transfected
APP (APP) in a DS astrocyte. APP immunostaining was performedCOS cells (Gabuzda et al., 1994). To further characterize
with antibody Alz-90.the potential role of energy deficits in the metabolism
(H–J) Double-labeling shows partial colocalization of A42 with syn-
of APP in the CNS, APP processing was analyzed in taxin 6 in the Golgi compartment of a DS astrocyte.
normal human astrocytes treated with the mitochondrial (K–M) Double-labeling shows partial colocalization of A42 with the
early endosomal antigen 1 (EEA1) in endosomal vesicles. Scale bar:electron chain uncoupler carbonyl cyanide m-chloro-
20 m.phenylhydrazone (CCCP) (Fries and Rothman, 1980; Ga-
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levels of APPs and C83, and intracellular accumulation
of detergent-resistant aggregates of A42.
Mitochondrial Dysfunction in DS Astrocytes
The similarity in the alterations in APP processing ob-
served in DS and CCCP-treated normal astrocytes
raised the possibility that a mitochondrial energy deficit
could be the cause of altered APP processing in DS
astrocytes. We investigated mitochondrial function by
assessing mitochondrial transmembrane potential (m)
in viable DS and normal astrocytes using the fluorescent
probe JC1 (Reers et al., 1991, 1995). JC1 is a positively
charged carbocyanine dye that accumulates in the inner
mitochondrial membrane where it forms monomers at
depolarized potentials, producing a green fluorescence
emission at 527 nm. At higher membrane potentials,
indicative of mitochondrial activity, JC1 forms multimers
called J aggregates, producing a red fluorescence emis-
sion at 590 nm (Figure 4A). Hence, reduced mitochon-
drial activity results in reduced JC1 aggregation and
decreased red fluorescence. Normal and DS astrocyte
cultures were incubated with JC1 and analyzed by fluo-
rescence microscopy. Under these conditions, 72.9%
7.3% of normal astrocytes exhibited JC1 red fluores-
cence, indicative of active mitochondria (Figures 4B and
Figure 3. Mitochondrial Dysfunction in Normal Astrocytes Induces 4D). The number of DS astrocytes exhibiting J aggre-
Aberrant APP Processing and Intracellular A Accumulation
gates was significantly reduced to 42% 5.6% (Figures
(A) Normal astrocytes treated with CCCP exhibit increased cellular
4C and 4D), despite similar cellular loading of JC1 asAPP (APP) and decreased levels of secreted APP (APPs). Samples
measured by JC1 emission intensity at 427 nm. As ex-were separated in a 4%–20% gradient gel, electroblotted, and incu-
pected, normal astrocytes treated with CCCP, an agentbated with antibodies C8 (cellular) and Alz-90 (secreted).
(B) Treatment with CCCP reduces C83 and increases C99 levels in that abolishes the mitochondrial electrochemical gradi-
normal astrocytes. Shown are Western blots with antibody C8, which ent, showed a dramatic decrease in the number of
recognizes APP C-terminal fragments, and 6E10, which recognizes astrocytes exhibiting J aggregates (16.7%  4.9%; Fig-C99, but not C83.
ure 5D). Thus, DS astrocytes exhibit significantly re-(C–F) Accumulation of intracellular A42 in CCCP-treated astro-
duced mitochondrial transmembrane potential.cytes. Immunofluorescence was performed on CCCP-treated and
control astrocytes with antibody -A42. Nuclei were counter- To further examine mitochondrial function in DS, we
stained with propidium iodide. Intensely labeled aggregates of A42 assessed reduction of the MTT reagent (3-[4,5-dimethyl-
are localized throughout the cytoplasm after treatment with CCCP thiazol-2-yl]-2,5-diphenyltetrazolium bromide) as an
([D and F], arrows) and are detergent-insoluble (F). Scale bar: 20
assay of mitochondrial redox activity (Mosmann, 1983).m.
MTT is reduced to formazan by mitochondrial succinate
dehydrogenase in complex II (succinate: ubiquinone oxi-
doreductase complex), which plays a central role in bothbuzda et al., 1994). Energy depletion in normal
oxidative phosphorylation and the tricarboxylic acid cy-astrocytes significantly increased the amount of cellular
cles (Hatefi, 1985). MTT-reducing activity was reducedAPP by 20.2% 4.3% (p 0.002) and C99 by 50.6%
by approximately 30% in DS cultures (p  0.01) (Figure8.7% (p  0.001) and reduced the levels of C83 and
4E). A similar result was obtained using another mito-APPs by 46.7%  7.7% (p  0.001) and 49.6%  2%
chondrial redox assay utilizing the soluble tetrazolium(p 0.0001), respectively (Figures 3A and 3B). Secreted
compound MTS (3-[4,5-dimethylthiazol-2-yl]-5-[3-car-A levels were also reduced by CCCP treatment (data
boxymethoxyphenyl]-2-[4-sulphophenyl]-2H-tetrazo-not shown). These changes are reminiscent of the alter-
lium) (data not shown). Trypan blue and propidium io-ations in APP processing in DS astrocytes.
dide exclusion assays showed no significant differencesImmunocytochemical analysis of normal astrocytes
in the number of viable cells in normal and DS culturesafter exposure to CCCP showed the presence of A42
(Figure 4F), indicating that the decrease in mitochondrialaggregates throughout the cytoplasm from perinuclear
redox activity in DS cultures was not due to decreasedregions to the cell membrane (Figures 3D and 3F,
cell viability. Furthermore, analysis of cytochrome C lev-arrows). The A42 aggregates were resistant to solubili-
els by Western blotting did not show a significant differ-zation with Triton X-100 (Figure 3F) and, similar to A42
ence between normal and DS astrocytes, suggestingaggregates in DS astrocytes, partially colocalized with
that mitochondrial protein content was not different inER, Golgi, and endosomal markers (data not shown).
DS cultures (data not shown). Taken together, theseThus, DS and energy-depleted normal astrocytes exhibit
results suggest that mitochondrial energy metabolismstrikingly similar profiles of APP processing including
increased levels of cellular APP and C99, decreased is impaired in DS astrocytes.
APP Metabolism and Mitochondrial Dysfunction in DS
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Intracellular Accumulation of A1-42
in DS and AD Brains
We then determined whether the altered pattern of APP
processing associated with impaired mitochondrial
function also appeared in vivo in the DS brain. First, we
determined whether intracellular A42 accumulates in
DS brains as it does in DS astrocyte cultures. Intracellu-
lar A42 labeling was detected in cortical pyramidal
neurons in the brain of a 36-year-old DS patient that
also exhibited scattered diffuse extracellular A42 de-
posits but lacked mature A plaques or neurofibrillary
tangles (Figure 5A). A immunoreactivity was com-
pletely abolished by preincubation of the primary anti-
body with synthetic A1-42 (Figure 5B). Much weaker
intracellular labeling for A42 was observed in scattered
neurons in the cortex and hippocampal formation of a
41-year-old normal subject (data not shown). Intense
intracellular A42 labeling was also observed in cortical
sections from five different DS patients with advanced
AD neuropathology. Intraneuronal staining was ob-
served in the parietal cortex, entorhinal cortex, and hip-
pocampal formation (Figure 5C). A42 labeling extended
throughout the neuronal cytoplasm including primary
dendrites and, in some cases, secondary dendrites as
well (Figures 5C and 5D). A42 labeling was also de-
tected in the cytoplasm and processes of cortical
astrocytes in two of the five DS cases analyzed (Figure
5E). Astrocytic identity was confirmed by double-label-
ing with GFAP (data not shown). Thus, intracellular A42
accumulates in neurons and astrocytes in the DS brain
and may precede the formation of amyloid plaques and
neurofibrillary tangles.
Significant experimental evidence indicates that A
can be neurotoxic both in vitro and in vivo (Yankner,
1996; Geula et al., 1998). To determine whether the pres-
ence of intracellular A42 is associated with neuronal
cell death, we analyzed the relationship between intra-
Figure 4. Impaired Mitochondrial Function in DS Astrocytes cellular A42 and neuronal degeneration in DS and AD
(A) Normal and DS astrocytes were labeled with the mitochondrial brain sections. A42 was clearly detected in the cyto-
transmembrane potential-sensitive dye JC1. JC1 fluoresces green plasm of TUNEL-positive neurons in the cortex of DS
(527 nm) or red (590 nm) depending on whether mitochondria are patients with AD pathology, as well as in sporadic AD
relatively less or more activated. A normal astrocyte (NL) labeled
cases and familial AD cases with presenilin mutationswith JC1 shows inactive and active mitochondria, which are labeled
(Figures 5F and 5G, arrows). Intracellular A was alsogreen and red, respectively (see Experimental Procedures).
found in TUNEL-negative cells, suggesting that Aaccu-(B and C) DS astrocytes labeled with JC1 and visualized with the
red channel show reduced numbers of cells with active mitochondria mulation may precede neuronal degeneration (Figure
(arrows) and more cells with inactive mitochondria (arrowheads) 5F, arrowheads). Most TUNEL-positive neurons exhib-
relative to normal astrocytes. Astrocyte nuclei are labeled with ited shrinkage of the cell body and chromatin condensa-
Hoechst 33258 (blue channel).
tion, consistent with neuronal apoptosis (Figures 5F–(D) Quantitative analysis shows a significant decrease in the number
5H). Moreover, A42 staining was observed in manyof DS astrocytes exhibiting red JC1 labeling (42%  5.6%) com-
TUNEL-positive cells that exhibited loss of cellular mem-pared to normal astrocytes (72.9%  7.3%). CCCP treatment of
normal astrocytes markedly reduces the number of cells exhibiting brane integrity and cytoplasmic vacuolization (Figure
red JC1 labeling (16.7%  4.9%). Values are the mean  SEM; 5H, arrow). Thus, intracellular A42 appears to be asso-
n  four independent experiments. *p  0.01 relative to control by ciated with neuronal apoptosis in DS and AD brains and
Student’s t test.
may become deposited in the extracellular space.(E) Reduced mitochondrial redox activity in DS astrocytes. MTT-
reducing activity in DS cultures was significantly reduced relative to
normal cultures. Values are the mean  SEM; n  four independent Decreased APP Secretion in the DS Brain
experiments; *p  0.01 relative to control by Student’s t test. The analysis of APP metabolism in DS astrocyte cul-
(F) Trypan blue exclusion assay shows no significant differences in tures showed a significant decrease in APPs secretion
cell viability between normal and DS cultures. Values are the mean
(Figure 1A). To determine whether this defect also oc-SEM; n  four independent experiments.
curs in vivo, the levels of APPs and holo-APP were
determined in the cortex of normal and DS brains. After
tissue homogenization, APPs and holo-APP were an-
alyzed by Western blotting of fractions enriched in solu-
Neuron
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Figure 5. Intracellular Accumulation of A42
in DS and AD Cortex
(A) Intracellular A42 immunoreactivity in the
cytoplasm of pyramidal neurons (arrows) in
the cortex of a 36-year-old DS patient.
(B) Preabsorption of the primary antibody
with synthetic A1-42 completely abolishes
immunostaining in a section adjacent to that
shown in (A).
(C and D) -A42 immunoreactivity in pyrami-
dal neurons in the hippocampus of a 62-year-
old DS patient exhibiting AD neuropathology.
A42 immunoreactivity is localized predomi-
nantly in neuronal cell bodies (arrows) and
dendritic processes (arrowheads).
(E) A42 immunoreactivity in astrocytes
(arrows) in the cortex of a DS patient with AD.
Astrocytic identity was confirmed by double-
labeling with GFAP (data not shown).
(F and G) Double labeling for A42 (red) and
TUNEL (brown) in DS (F) and familial AD (G)
brain sections. Note the intense staining for
A42 in cortical cells exhibiting TUNEL-posi-
tive nuclear staining (arrows). A42 immuno-
reactivity is also observed in neurons that are
TUNEL-negative and exhibit intact morphol-
ogy (arrowheads).
(H) High-magnification view of a DS cortical
neuron that exhibits granular A42 immuno-
reactivity (arrow) and degenerative features
including shrinkage of the soma, lack of mem-
brane integrity, and positive TUNEL staining
(arrowhead). Scale bars: 20 m (A–C and
E–G); 10 m (D); 5 m (H).
ble or membrane-associated proteins, respectively. Holo- al., 1994; Mattson, 1997). DS cortical neurons undergo
increased degeneration after the first week in cultureAPP was detected in the membrane-enriched fraction
with both the C8 and 8E5 antibodies (Figure 6A). APPs (Busciglio and Yankner, 1995), and they also exhibit in-
creased A accumulation and decreased APPs secre-was detected in the fraction enriched in soluble proteins
by Western blotting with antibody 8E5 directed against tion (Figure 1F). To determine whether APPs could
rescue DS neurons, DS neuronal cultures were incu-residues 444–592 of APP695, but was not detected by
antibody C8, which is directed against the C terminus of bated with recombinant APPs spanning residues 20 to
590 of APP695 (Roch et al., 1992) or a 17-mer peptideAPP (Figure 6A). Samples of brain tissue were obtained
from three different cortical regions of five DS specimens comprising the putative neurotrophic domain of APPs
corresponding to amino acids 310–335 (Bowes et al.,and five normal specimens. The samples were homoge-
nized, fractionated, and analyzed by SDS-PAGE. After 1994; Roch et al., 1994). Incubation of DS cultures with
either recombinant APPs or the 17-mer peptide dra-densitometric quantification, the results were expressed
as the average ratio of APPs/holo-APP in DS and matically increased DS neuronal survival (Figure 7A). In
contrast, no significant effects on neuronal survival werenormal cortex. A significant reduction of 47.1%  4.6%
was observed in the ratio of APPs/holo-APP in DS observed in DS cultures incubated with a reverse se-
quence control peptide or with the neurotrophic factorsbrains compared to controls (Figure 6B). When the sam-
ples were separated and grouped by age, including new- NGF, BDNF, or NT3 (Figure 7A). Thus, APPs, but not
other neurotrophic factors, prevents the degenerationborns, young adults, and mature cases, the reduction
in DS APPs/holo-APP ratio was observed at all devel- of DS neurons. In contrast, APPs did not significantly
affect neuronal survival in normal cortical cultures (Fig-opmental stages (Figure 6C). Two sporadic AD cases
also showed significantly reduced ratios compared to ure 7A).
To confirm a role for diminished APP secretion inan age-matched control (p  0.05) (Figure 6B). These
results suggest that, similar to cultured DS astrocytes, DS neuronal degeneration, DS cortical neurons were
incubated with the conditioned medium of normal or DSthere is reduced APPs in the DS cortex throughout life.
Moreover, reduced cortical levels of APPs may also astrocytes from days 7–14 in culture. Normal astrocyte-
conditioned medium dramatically increased DS neu-occur in sporadic AD.
ronal survival, whereas DS astrocyte-conditioned me-
dium did not increase DS neuronal survival (Figure 7B).APPs Rescues DS Cortical Neurons
from Apoptosis DS cultures incubated with conditioned medium of nor-
mal astrocytes that had been depleted of APPs byPrevious studies suggest that APPs may possess both
neurotrophic and neuroprotective activities (Mattson et immunoprecipitation did not exhibit increased neuronal
survival (Figure 7B). Taken together, these results indi-al., 1993; Goodman and Mattson, 1994; Yamamoto et
APP Metabolism and Mitochondrial Dysfunction in DS
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Figure 6. Decreased APPs in the DS Cortex
(A) Western blot analysis of normal (NL) and DS cortical homoge-
nates. Membrane-enriched and soluble fractions were separated in
Figure 7. APPs Prevents the Degeneration of DS Cortical Neuronsa 7% acrylamide gel, electroblotted, and probed with antibody C8
(A) DS cortical neuronal cultures were incubated with recombinantagainst APP C terminus and 8E5 against the APP ectodomain.
APP (200 nM), an APP-derived trophic peptide (17-mer; 500 nm),As expected, holo-APP (APP) appears in the membrane-enriched
the reverse sequence peptide (17-mer-rev; 500 nm), or the neuro-fraction, but not in the soluble fraction, while APPs (APPs) appears
trophic factors NGF (40 ng/ml), BDNF (40 ng/ml), or NT3 (40 ng/ml)in the soluble fraction and is selectively recognized by 8E5. Similar
from days 7 to 14 in culture. Neuronal viability at day 14 is expressedprotein loading was confirmed by blotting with anti--tubulin.
as percent of the neuronal number at day 7 (100%). Neuronal viability(B) Decreased APPs in DS cortex. Cortical tissue samples from
in untreated DS cultures was reduced to 45% 4.8%. Recombinantfive normal (NL) and five DS brains were analyzed by quantitative
APP and the 17-mer peptide prevent DS neuronal degeneration,Western blotting and the ratio of APPs/holo-APP was determined
whereas the 17-mer reverse peptide, NGF, BDNF, and NT3 did notas described in Experimental Procedures. Note the significant de-
affect DS neuronal survival. Values are the mean  SEM; n  fourcrease in APPs in DS brains. Values are the mean  SEM; n  5;
independent experiments; *p  0.01 by Student’s t test.*p  0.01 relative to control by Student’s t test.
(B) A significant increase in neuronal survival is observed in DS(C) Brain specimens were grouped according to patient age from 3
cultures incubated with conditioned medium of normal astrocytemonths (M) to 81 years (Y). A significant decrease in APPs is ob-
cultures (cm/NL APP	), but not with conditioned medium of DSserved in DS brains at all developmental stages. Values are the
astrocyte cultures (cm/DS) or with conditioned medium of normalmean  SEM. n  three different cortical samples per brain. Aster-
astrocytes depleted of APP by immunoprecipitation (cm/NL APP
).isks indicate statistical significance relative to control(s) of the same
Neuronal viability determined at day 14 in culture is expressed asage group (*p  0.05) by Student’s t test.
percent of the neuronal number at day 7 (100%). Values are the
mean  SEM; n  three independent experiments; *p  0.01 by
Student’s t test. The immunoblot in the right panel confirms the
cate that APPs is a neuroprotective agent for DS corti- complete depletion of APPs from the conditioned medium (cm) of
normal astrocyte cultures after immunoprecipitation with a mixturecal neurons and that reduced levels of APPs may com-
of Alz-90 and 8E5 monoclonal antibodies (-APP). A single bandpromise neuronal survival in DS and AD.
corresponding to APPs is detected in the -APP immunprecipitate
(IP, -APP). In contrast, APPs remains in the conditioned medium
after immunoprecipitation with nonimmune mouse IgG (cm, NI) andDiscussion
is absent in the immunoprecipitated fraction (IP, NI).
These experiments indicate that there is a marked alter-
ation in APP processing and A trafficking in cortical is impaired in DS astrocytes, as indicated by reduced
mitochondrial redox activity and membrane potential.DS astrocytes and neurons that can be replicated in
normal human astrocytes by inhibition of mitochondrial However, despite impaired mitochondrial function, DS
astrocytes are completely viable in culture. We suggest,energy metabolism. Moreover, mitochondrial function
Neuron
684
therefore, that impaired energy metabolism in DS cells have found that intracellular A42 appears in TUNEL-
positive neurons in DS and AD brains, raising the possi-gives rise to increased -secretase cleavage of APP
and altered A trafficking resulting in intracellular accu- bility that it may contribute to neuronal degeneration.
In this regard, increased intracellular A42 has beenmulation of aggregated A42. Similar patterns of APP
processing were detected in the DS brain. These results associated with apoptosis, but not necrosis (Ohyagi et
al., 2000). However, intracellular A42 is also detectedraise the possibility that impaired mitochondrial energy
metabolism in the DS brain may contribute to the patho- in neurons with intact morphology and negative TUNEL
labeling (Figure 5F). Thus, intracellular accumulation ofgenesis of AD.
We have also observed a similar impairment in mito- A may be an early event in the pathological cascade
in AD, but its role in the neurodegenerative processchondrial function in primary cultures of DS fibroblasts
(A.P., B.A.Y., and J.B., unpublished data), suggesting remains to be determined.
The finding that there is reduced A secretion in DSthat mitochondrial dysfunction may be widespread in
DS. Previous reports suggest that the expression of astrocytes is not necessarily inconsistent with the early
deposition of A42 in diffuse plaques in DS patients.some mitochondrial proteins may be reduced in DS
(Krapfenbauer et al., 1999; Kim et al., 2000). In addition, For example, mutations in APP that favor A protofibril
formation and oligomerization can lead to AD even inimpaired mitochondrial function has been observed in
cortical cultures from trisomy 16 mice, a model that the presence of reduced production and secretion of
A (Nilsberth et al., 2001). In DS, oxidative stress andmimics some of the features of DS (Schuchmann et al.,
1998; Schuchmann and Heinemann, 2000). Moreover, energy deficits may play critical roles by promoting A
oligomerization and deposition despite initially reducedseveral studies suggest that energy deficits alter signal
transduction pathways, leading to increased cytosolic levels of extracellular A.
A neuroprotective function of the secreted ectodo-calcium levels and aberrant activation of protein kinases
in the AD brain (Bush et al. 1995; Luo et al., 1997). main of APP has been suggested by several studies
(Mattson et al., 1993; Bowes et al., 1994; Goodman andThe appearance of intracellular A has been reported
in a number of different experimental systems (Wertkin Mattson, 1994; Roch et al., 1994; Yamamoto et al., 1994;
Barger and Mattson, 1996; Mattson, 1997; Perez et al.,et al., 1993; Martin et al., 1995; Hartmann et al., 1997;
Wild-Bode et al., 1997; Xu et al., 1997; Skovronsky et 1997). Our results show that APPs is significantly re-
duced in DS astrocytes in culture and in the DS brainal., 1998; Perez et al., 1999). We have found that intracel-
lular A accumulates in a detergent-resistant form in DS throughout life, starting as early as 5 months of age. In
addition, cortical levels of APPs were reduced in casesastrocytes and in normal astrocytes treated with the
mitochondrial uncoupler CCCP. Intracellular A42 par- of late-onset sporadic AD. Similarly, a reduction in
APPs has been reported in the cerebrospinal fluid of ADtially colocalizes with APP and appears predominantly
in the Golgi complex and endosomal vesicles. It has patients (Van Nostrand et al., 1992). DS cortical neuronal
cultures, which also exhibit reduced levels of APPs,previously been shown that intracellular A42, APP,
and C-terminal fragments accumulate in a detergent- show a dramatic recovery in neuronal survival after incu-
bation with recombinant APPs or a 17-mer peptideinsoluble form in APP-overexpressing cells incubated
with 20 M synthetic A1-42 (Yang et al., 1995, 1999). corresponding to a neurotrophic/neuroprotective do-
main of APP. DS neuronal survival was also signifi-Our results suggest that a similar phenomenon may occur
under physiological conditions in DS astrocytes and in cantly increased by incubation with conditioned medium
of normal astrocytes, but not by DS medium or normalnormal astrocytes under conditions of impaired energy
metabolism. We have also detected detergent-insoluble astrocyte medium depleted of APP by immunoprecipi-
tation. In contrast, a variety of other neurotrophic fac-APP that cosediments with intracellular A in deter-
gent-resistant pellets of DS cell lysates and brain ho- tors, including NGF, BDNF, and NT3, do not improve
DS neuronal survival in our in vitro model. Taken to-mogenates (A.P., B.A.Y., and J.B., unpublished data).
These results provide evidence for an alternative pro- gether, these results suggest that APPs may be a sur-
vival factor for human neurons and underscore the po-cessing pathway in DS cells in which A42, APP, and
potentially amyloidogenic fragments accumulate and tential pathological relevance of reduced APPs levels
in DS and AD.form detergent-resistant aggregates.
Significant intracellular accumulation of A42 was de- We suggest that chronic APP overexpression in DS
may impair mitochondrial function, which in turn in-tected in DS brains both before and after the onset of
AD neuropathology. A42 appeared in the cell body and creases intracellular accumulation of A and reduces
secretion of neuroprotective APPs. Impaired mito-primary processes of neurons and astrocytes, raising
the possibility that both neurons and astrocytes contrib- chondrial function could result from direct toxic effects
of A (Yankner, 1996) or from the metabolic cost ofute to A generation and deposition in the DS brain.
Intracellular A42 was also detected in the brain of a clearing aggregated proteins through chaperones and
the degradative apparatus, processes that are highlyyounger DS patient exhibiting diffuse extracellular A42
deposition but devoid of mature plaques, tangles, and energy dependent. This model may also apply to other
chronic neurodegenerative diseases characterized bygeneralized features of neuronal degeneration, indicat-
ing that intracellular accumulation of A may precede intracellular protein aggregation, such as polyglutamine
repeat disorders, synucleinopathies, and tauopathies.plaque and tangle formation and neuronal death. This
observation is in agreement with the findings of Gouras The metabolic cost of chronic protein aggregation in
these diseases may lead to a state of impaired mito-et al. (2000), which suggest that intracellular A appears
in the brains of nondemented control subjects, AD pa- chondrial function and ATP depletion, giving rise to a
pathological feedback loop in which protein aggregationtients, and young individuals with DS. In addition, we
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were also homogenized in RIPA buffer; membrane-enriched andincreases and mitochondrial function is impaired further.
soluble fractions isolated as previously described (Lorenzo et al.,Furthermore, impaired energy metabolism would in-
2000) were mixed 1:1 with SDS-reducing sample buffer and boiledcrease neuronal vulnerability to exogenous toxic insults
for 5 min, followed by 7% or 4%–20% SDS-PAGE. The proteins
such as reactive oxygen species, giving rise to a sto- were then electrotransferred to polyvinylidene difluoride mem-
chastic process of neuronal cell death, consistent with branes, blocked, and incubated overnight at 4C with primary anti-
body and developed by enhanced chemiluminescence (Kirkegaardrecent mathematical models of cell death in neurode-
and Perry Laboratories). To control for protein loading, tubulin levelsgenerative diseases (Clarke et al., 2000). As such, thera-
were analyzed in all samples with anti -tubulin (clone DM1A;peutic strategies should be targeted to the prevention
Sigma). Quantitative analysis was performed using a FastScan den-of protein aggregation and the restoration of normal
sitometer (Molecular Dynamics) as described (Pigino et al., 2001).
mitochondrial function. Briefly, a standard curve of pixel values was constructed by immu-
noblotting a serial dilution of purified tubulin, and volume analysis
Experimental Procedures on the appropriate bands was performed using NIH Image software.
All densitometric values used for analysis were within the linear
Cell Culture range of pixel values.
Primary human cortical cultures were established from the cerebral
cortex of 17- to 21-week gestation normal and DS fetal abortuses.
12 DS brain specimens and 12 age-matched controls were used to Immunocytochemistry
generate neuronal and astrocyte cultures. The protocol for tissue Cultured cells were fixed for 30 min at 37C in 4% paraformaldehyde
procurement complied with federal and institutional guidelines for and 0.12 M sucrose in PBS and permeabilized with 0.1% Triton
fetal research. Cortical astrocyte cultures were prepared as pre- X-100 in PBS. For some experiments, the cultures were extracted
viously described (Busciglio et al., 1993b). Cells were plated on prior to fixation with 0.2% Triton X-100 as described (Busciglio
culture dishes or glass coverslips at a density of 100,000 cells/cm2 et al., 1995). Immunofluorescence of intracellular A in cultured
and maintained in 10% iron-supplemented calf serum (Hyclone) and astrocytes was performed using a tyramide signal amplification kit
D-MEM (Life Technologies). For all experiments, astrocyte cultures (NEN Life Science Products). Double immunofluorescence was per-
were fixed or harvested between 30 and 35 days in vitro. More than formed as described (Pigino et al., 2001). Specificity was confirmed
95% of the cells present in the cultures stained positive for GFAP by preabsorption of the primary antibody with synthetic A1-42
(Busciglio et al., 1993b). Normal and DS cortical neuronal cultures peptide, which abolished immunoreactivity. Fluorescence was visu-
were prepared as previously described (Busciglio et al., 1993a; Bus- alized with an Olympus IX-70 inverted microscope or a Zeiss LSM
ciglio and Yankner, 1995). 410 confocal-scanning microscope. Immunocytochemistry in nor-
mal, DS, and AD formalin-fixed, paraffin-embedded brain tissue
Antibodies sections was performed as previously described (Busciglio et al.,
C8 is a polyclonal antibody directed against residues 676–695 of 1997). Terminal deoxynucleotidyl transferase-mediated dUTP nick
APP, which recognizes holo-APP and C-terminal fragments. end labeling (TUNEL) was performed using the Apoptag kit (Intergen)
Alz90 (Roche) and 8E5 (supplied by Dr. Peter Seubert, Elan Pharma- as described (Shi et al., 1996).
ceuticals) (McConlogue et al., 1996) are monoclonal antibodies that
recognize residues 511–608 and 444–592, respectively, in the
APP695 ectodomain and recognize APPs. B9 is a polyclonal anti- Inhibition of Energy Metabolism
body generated against synthetic A1-40 peptide. The monoclonal To inhibit mitochondrial energy metabolism, normal astrocyte cul-
antibody 6E10 recognizes A residues 1–17 (Senetek). Monoclonal tures were incubated with 80 M of CCCP for 4 hr before harvesting
antibodies -A42 and -A40 specifically recognize the free for biochemical analysis. For immunofluorescence microscopy of
C terminus of Ax-42 and Ax-40, respectively (Lippa et al., 1999). intracellular A, astrocytes were incubated with 20 M CCCP for 3
Other antibodies used included anti-syntaxin 6 and anti-early endo- days and with 80 M CCCP for 4 hr before fixation. Under these
somal antigen 1 (Signal Transduction Laboratories), mouse anti- conditions, CCCP did not reduce astrocyte survival as determined
GFAP (Roche) and rabbit anti-GFAP (Sigma), mouse anti-actin by propidium iodide exclusion.
(Sigma), rabbit anti-flotillin (supplied by Dr. P. Bickel, Dept. Cell
Biology, Washington University School of Medicine, St. Louis, MO),
mouse anti--tubulin and anti--tubulin isotype III (Sigma), mouse Assessment of Mitochondrial Function
Mitochondrial redox activity was analyzed in normal and DSanti-Cu/Zn superoxide dismutase (Sigma), mouse anti-1-antichy-
motrypsin (Dako) and rabbit anti-syndecan (supplied by Dr. M. astrocyte cultures using MTT and MTS reduction assays following
the vendor’s protocol (Promega). Mitochondrial transmembrane po-Bernfield, Division of Newborn Medicine, Children’s Hospital,
Boston, MA). tential was analyzed using the carbocyanine dye JC1 (Molecular
Probes) (Reers et al., 1991). Astrocyte cultures were incubated with
0.25% trypsin for 5 min, dissociated, and replated at a lower densityMetabolic Labeling and Immunoprecipitation
Metabolic labeling was performed as described (Busciglio et al., (50,000 cells per cm2). 24 hr after replating, a dose-response curve
was constructed to determine a nonsaturating concentration of JC11993b). Briefly, 4  106 astrocytes per 10 cm plate were labeled
with [35S]methionine (200 Ci/ml) in methionine-free D-MEM plus in normal astrocyte cultures. Under these conditions, a 30 min incu-
bation with 0.5 M JC1 resulted in approximately 70% of normal10% calf serum for 12 hr at 37C. Labeled cells were harvested in
cold RIPA lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate, astrocytes exhibiting red fluorescent J aggregates (Figure 4). Normal
and DS astrocytes were incubated with 0.5 M JC1 for 30 min, and0.1% SDS, 150 mM NaCl, 50 mM Tris-HCl, [pH 7.2]) supplemented
with protease inhibitors (Complete, Roche). Immunoprecipitation equivalent cellular loading of the dye in normal and DS cultures was
confirmed by quantification of JC1 emission intensity at 527 nmand preabsorption protocols have been previously described (Bus-
ciglio et al., 1993b). Samples were normalized for protein content using NIH image software as described (Pigino et al., 2001). Then,
the number of individual astrocytes exhibiting J aggregates (emis-of the cell lysates and resolved by SDS-PAGE in 7% Tris-glycine
or 10%–20% Tris-tricine gels. Band intensity was quantitated by sion at 590 nm) and the total number of astrocytes (emission at 527
nm) was quantified by image analysis of 10 microscopic fields perPhosphorImager scanning using ImageQuant software (Molecular
Dynamics). culture. Equivalent astrocyte cell number in the cultures was further
confirmed by scoring fluorescent nuclei after staining with Hoechst
33258. All experiments were performed blinded and in quadruplicateWestern Blot Analysis
For Western blot analysis, cell cultures were washed with PBS and cultures. Approximately 450 cells were analyzed per experimental
condition. Cell viability in cultures used for MTT, MTS, and JC1-harvested in RIPA buffer at 4C. The lysates were centrifuged at
100,000  g for 60 min. RIPA-insoluble pellets were solubilized by assays was assessed using propidium iodide or trypan blue exclu-
sion assays (Busciglio et al., 1995).boiling in 4% SDS in Tris-HCl, (pH 6.8), for 10 min. Brain samples
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Neuroprotection Assays localization of presenilin-1 and association with amyloid plaques
and neurofibrillary tangles in Alzheimer’s disease. J. Neurosci. 17,Treatment of DS neuronal cortical cultures growing in 24-well plates
was initiated at day 7, before the onset of neuronal degeneration 5101–5107.
(Busciglio and Yankner, 1995). A recombinant form of APP com- Bush, M.L., Miyashiro, J.S., and Ingram, V.M. (1995). Activation of
prising amino acids 20–590 of APP695, 17-mer, and 17-mer reverse a neurofilament kinase, a tau kinase, and a tau phosphatase by
sequence peptides, kindly supplied by Dr. J.M. Roch (Roch et al., decreased ATP levels in nerve growth factor-differentiated PC-12
1992, 1994), were diluted in PBS and immediately added to the cells. Proc. Natl. Acad. Sci. USA 92, 1861–1865.
culture medium at the indicated concentrations. NGF, BDNF, and
Clarke, G., Collins, R.A., Leavitt, B.R., Andrews, D.F., Hayden, M.R.,
NT3 (supplied by Dr. M. Greenberg, Division of Neuroscience, Chil-
Lumsden, C.J., and McInnes, R.R. (2000). A one-hit model of cell
dren’s Hospital, Boston, MA) were added to the culture medium at
death in inherited neuronal degenerations. Nature 406, 195–199.
a final concentration of 40 ng/ml. At days 9 and 11, a 30% partial
Coyle, J.T., Oster-Granite, M.L., and Gearhart, J.D. (1986). The neu-medium change was performed and the treatment was repeated.
robiologic consequences of Down syndrome. Brain Res. Bull. 16,The cultures were fixed at day 14, immunostained with anti--tubulin
773–787.class III, and the number of viable neurons was scored in quadrupli-
Druzhyna, N., Nair, R.G., LeDoux, S.P., and Wilson, G.L. (1998).cate cultures as previously described (Busciglio and Yankner, 1995).
Defective repair of oxidative damage in mitochondrial DNA inMore than 400 neurons were scored per experimental condition.
Down’s syndrome. Mutat. Res. 409, 81–89.For some experiments, DS neurons were incubated with conditioned
medium of DS astrocyte cultures, normal astrocyte cultures, or with Frederikse, P.H., Garland, D., Zigler, J.S., Jr., and Piatigorsky, J.
normal astrocyte- conditioned medium previously depleted of se- (1996). Oxidative stress increases production of beta-amyloid pre-
creted APP by immunoprecipitation with a mixture of antibodies cursor protein and beta-amyloid (Abeta) in mammalian lenses, and
Alz-90 and 8E5. The absence of APPs in the conditioned medium Abeta has toxic effects on lens epithelial cells. J. Biol. Chem. 271,
after immunoprecipitation was confirmed by Western blot. 10169–10174.
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